title: Intermittent androgen suppression for prostate cancer: rationale and clinical experience.
abstract: The rationale behind intermittent androgen suppression (IAS) is based on: (1) observations that androgen ablation is palliative, not curative, in most patients with prostate cancer, and that quality of life must be considered; (2) the assumption that immediate androgen ablation is superior to delayed therapy in improving survival; (3) the hypothesis that if tumour cells surviving androgen withdrawal are forced into a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored and progression to androgen independence delayed. Several centres have now tested the feasibility of IAS therapy in non-randomized groups of prostate cancer patients using serum of prostate-specific antigen levels as trigger points. Clinical data suggest that prostate cancer is amenable to control by IAS and offers clinicians an opportunity to improve patients' quality of life by balancing the benefits of immediate androgen ablation (delayed progression and prolonged survival) while reducing treatment-related side effects and expense. Whether time to progression and survival is affected in a beneficial or adverse way is being studied in randomized, prospective protocols.
authors.affiliation: Division of Urology, Vancouver General Hospital, University of British Columbia, Canada. gleave@unixg.ubc.ca
authors.forename: M
authors.initials: M
authors.lastname: Gleave
authors.forename: N
authors.initials: N
authors.lastname: Bruchovsky
authors.forename: S L
authors.initials: SL
authors.lastname: Goldenberg
authors.forename: P
authors.initials: P
authors.lastname: Rennie
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000728:Androgens / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011788:Quality of Life; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000970:Antineoplastic Agents; D013739:Testosterone; D017430:Prostate-Specific Antigen